Employing the natural product quassinoid brusatol, we currently report cellular and molecular events leading to cell death or terminal differentiation in a panel of leukemic cells. Brusatol and bruceantin exerted significant cytotoxic effects with several leukemic cell lines, but not with K562 or normal lymphocytic cells. Cell lines that were less sensitive to the cytotoxic effects of brusatol responded primarily through induction of terminal differentiation. The differentiated phenotype in cell lines derived from acute or chronic myeloid leukemias (HL-60, K562, Kasumi-1, NB4, U937, BV173) was characterized for producing superoxide and non-specific esterase, and some with up-regulation of CD13 (cluster of differentiation) and downregulation of CD15. Chronic myeloid leukemic cell lines, K562 and BV173, and acute lymphoblastic cell lines, SUPB13 and RS4;11, were induced to differentiate along the erythrocytic pathway. Withdrawal studies showed that brusatol treatment for 48 h was sufficient to induce commitment towards terminal differentiation in HL-60, K562 and SUPB13. Reh cells did not undergo maturation. Analysis of c-MYC protein expression revealed that brusatol or bruceantin down-regulated expression to undetectable levels in cell lines that were most sensitive, based on cell death or terminal differentiation. Generally, c-myc RNA was reduced, but to a lower extent than c-MYC protein levels, indicating c-myc expression was regulated by quassinoids at the post-transcriptional level. Thus, regulation of c-myc expression may represent a critical event that leads to terminal differentiation. Since these responses are facilitated at clinically achievable concentrations, quassinoids may be of value for the management of hematological malignancies.
Introduction
The process of neoplastic cell growth can be depicted as a dysfunctional balance between control of cell proliferation, apoptosis and terminal differentiation. In normal cells, activation of specific pathways leads to cellular differentiation, which typically is accompanied by cell growth arrest followed by apoptosis. In many cancers, ie, leukemias, genetic changes (eg, chromosomal translocations, point mutations, gene amplifications or deletions) block the normal differentiation program. 1 Conventional cytotoxic chemotherapy focuses on cell killing effects in order to achieve complete hematological remissions (ie, less than 5% blasts). In the past few years, however, several non-conventional selective anti-leukemic agents have been developed that function by targeting molecules involved directly in the pathogenesis of the disease. For instance, all-trans-retinoic acid (ATRA) has revolutionized the treatment of acute promyelocytic leukemia (APL); complete remissions are attained without marrow hypoplasia or exacerbation of fibrinolysis. 2, 3 Although the mechanism of ATRA is still under investigation, it is known that binding with its natural receptor, RAR␣, results in the induction of granulocytic differentiation followed by apoptosis in APL-derived leukemic blasts. [4] [5] [6] Another selective agent, CGP57148B, inhibits enhanced Abelson leukemia (ABL) tyrosine kinase activity resulting from the BCR/ABL fusion gene that is characteristic of leukemias with the t(9;22); apoptosis is thereby induced selectively in these cases. 7 Some genes have been shown to be important in the development or malignancy of various types of leukemia and lymphoma, by inducing blockages in differentiation or apoptosis. Among them, c-myc gene amplifications and translocations resulting in its deregulation have been noted, particularly in Burkitt's lymphoma and acute lymphoblastic leukemia (ALL). 8, 9 Studies using c-myc knockout cell lines and c-myc antisense RNA have shown that reducing c-myc slows cell growth and induces differentiation in various cell lines. [10] [11] [12] [13] Moreover, regulation of c-MYC protein levels has proven to be an essential mode of action for various inducers of cellular differentiation. [14] [15] [16] [17] [18] [19] Brusatol ( Figure 1 ) is a quassinoid, ie, a type of degraded diterpenoid, obtained from Brucea species (Simaroubaceae). Brusatol and analogues are capable of inducing an array of biological responses including in vivo anti-inflammatory and antileukemic effects with murine models. 20 The major mechanism responsible for antineoplastic activity at the molecular level has been attributed to inhibition of protein synthesis. 21 Such inhibition has been shown to occur via interference at the peptidyltransferase site, thus preventing peptide bond formation. 22 Other cellular targets include inhibition of phosphoribosyl pyrophosphate aminotransferase of the de novo purine synthesis pathway and inhibition of DNA/RNA synthesis. 23 In order to assess toxicity, bruceantin (a structural analogue of brusatol) ( Figure 1 ) was evaluated in three separate phase I clinical trials in patients with various types of solid tumors. Hypotension, nausea and vomiting were common side-effects at higher doses, but hematologic toxicity was moderate to insignificant and manifested mainly as throm-
Figure 1
Chemical structures of brusatol and bruceantin.
bocytopenia. 24, 25 Bruceantin was then tested in two separate phase II trials including adult patients with metastatic breast cancer 26 and malignant melanoma. 27 No objective tumor regressions were observed and clinical trials were terminated.
In our program for the procurement of novel plant-derived chemotherapeutic/chemopreventive agents, we have used HL-60 cell differentiation activity as one marker of activity. 28 This led to the identification of brusatol as a potent inducer of HL-60 cell differentiation. 29 In order to test its potential efficacy as an anti-leukemic agent, we elected to evaluate the effect of brusatol with a panel of leukemic cells with representative chromosomal translocations and other gene mutations. Currently, we demonstrate that brusatol induces cell death events selectively in some cell lines, particularly those known to express wild-type p53, and induces terminal differentiation in the remaining cell lines. A significant finding was potent down-regulation of c-MYC oncoproteins; those cell lines expressing high levels of c-MYC oncoprotein were the most sensitive to brusatol-mediated effects. The decrease in c-MYC oncoprotein expression was due in part to transcriptional regulation, as shown by real-time RT-PCR, although the decrease in c-myc transcript levels was less than the decrease of c-MYC protein levels. The potent down-regulation of c-myc associated with terminal cell differentiation at physiologically achievable concentrations suggest that this compound is a strong candidate for leukemia chemotherapy.
Materials and methods

Materials
Brusatol was isolated from Brucea javanica 25 and bruceantin was obtained from the NCI (Bethesda, MD, USA). 1␣,25-Dihydroxyvitamin D 3 (VD 3 ) was supplied by Steroids (Chicago, IL, USA), and 12-O-tetradecanoylphorbol-13-acetate (TPA) was purchased from Chemsyn Science Laboratories (Lenexa, KS, USA). All other compounds were purchased from Sigma Chemical (St Louis, MO, USA). Test compounds were dissolved in DMSO (dimethylsulfoxide) and stored at −20°C. Cell culture medium was obtained from Gibco BRL (Gaithesburg, MD, USA). 3 H Thymidine was obtained from Amersham Life Sciences (Arlington Heights, IL, USA). Primary antibody for c-MYC (cat. No. OP10) was purchased from Oncogene (Cambridge, MA, USA), and secondary antibody was from Amersham Life Sciences (Arlington Heights, IL, USA). Primary antibody for ␤-actin was purchased from Sigma, USA and all reagents utilized for real time RT-PCR were from Applied Biosystems (Foster City, CA, USA).
Cell culture
HL-60, K562, U937, Reh and Daudi cells were obtained from the American Type Culture Collection (Rockville, MD, USA). Kasumi-1, NB4, BV173, SUPB13 and RS4;11 cells were provided by the Section of Hematology/Oncology, University of Illinois College of Medicine, Chicago, IL. All cell lines were maintained in suspension culture using RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum, 100 units of penicillin/ml and 100 g of streptomycin/ml at 37°C in a humidified atmosphere of 5% CO 2 in air. All cells were routinely tested for mycoplasma contamination.
Preparation of normal human lymphocytes
Human blood (20 ml) was collected in heparinized sterile tubes and white blood cells were separated using Ficoll reagent (8 ml/5 ml blood diluted in 15 ml Hank's buffered solution). After centrifugation at low speed (1500 r.p.m.) for 30 min, the white coat was removed and washed three-times with Hank's buffered solution. The cell pellet was resuspended in RPMI 1640 medium supplemented with 10% FBS. This preparation contained Ͼ90% lymphocytes and Ͼ5% monocytes as determined by Wright-Giemsa staining.
Cell differentiation assays
Cell lines were tested using a 4-day incubation protocol, unless otherwise specified. At the end of the incubation, cells were analyzed to determine the percentage exhibiting morphological, functional nitroblue tetrazolium (NBT) reduction, enzymatic non-specific/specific esterase (NSE/SE) and cell surface markers of differentiated cells, as described below. 28 
Cell morphology:
Aliquots of the cell suspension (2 × 10 5 cells/ml) were used to prepare cytospin smears which were stained with Wright-Giemsa. Morphological features of cellular differentiation (change in cytoplasmic pH, decrease in size, decrease of nuclear/cytoplasm ratio (or absence of nucleus), presence of specific granules or lysosomal vacuoles, lobulated nucleus) were monitored by light microscopy.
NBT/NSE/SE:
Evaluation of NBT reduction was used to assess the ability of sample-treated cells to produce superoxide when challenged with TPA. A 1:1 (v/v) mixture of a cell suspension (10 6 cells) and TPA/NBT solution (2 mg/ml NBT and 1 g/ml TPA in phosphate buffer saline (PBS) ) was incubated for 1 h at 37°C. Then, cells were smeared on glass slides, and counterstained with 0.3% (w/v) safranin O in methanol. Positive cells reduce NBT yielding intracellular blackblue formazan deposits. NSE/SE are monocytic/granulocytic esterases that can be visualized by cytochemical staining using commercially available kits (␣-Naphthyl Acetate Esterase and Naphthol As-D Chloroacetate Esterase kits, Sigma Chemical). Positive-stained cells were quantified by microscopic examination of Ͼ200 cells. Results were expressed as a percentage of positive cells.
Determination of cell surface antigen by flow cytometry:
Cells (10 6 ) were washed with PBS and then incubated for 30 min at room temperature with respective monoclonal antibodies, washed with 20 volumes of diluent (PBS with 0.1% sodium azide and 1% BSA), and resuspended in 0.5 ml of fresh diluent for evaluation. Necrotic cells were excluded from the analysis by propidium iodide (PI) staining. The following mAbs (Sigma) were used to assess the maturation level of myeloid cell lines: anti-CD15 (Leu M1), anti-CD-11b (OKM1), anti-CD14 and anti-CD13. 30 The following mAbs (Sigma) were used to assess the maturation level of lymphocytic cell lines: anti-CD20, anti-HLA-DR and anti-kappa light chain.
H thymidine incorporation into DNA was determined to assess the level of cell proliferation as well as DNA synthesis inhibition. Cells were treated with test samples for 4 days and then placed into 96-well plates (100 l) and treated with 3 H thymidine (0.5 Ci/ml, 65 Ci/mmol) for 18 h at 37°C in a 5% CO 2 incubator. Cells were then collected on glass fiber filters using a TOMTEC Harvester 96. The filters were counted using a Microbeta liquid scintillation counter (Wallac, Turku, Finland) with scintillation fluid. Finally, the percentage of 3 
Analysis of DNA content with flow cytometry
About 10 6 cells from each sample were collected and washed twice with ice-cold PBS, fixed in 70% ethanol, and stored at 4°C until analysis. The cells were stained with PI (50 g/ml), treated with DNase-free RNase (10 g/ml), and subjected to DNA content analysis using an EPICS Coulter flow cytometer. At least 10 000 cells were counted for each sample. The percentage of apoptotic cells was calculated by measuring the area under the subdiploid (DNA Ͻ2 N) peak in the plot of cell number against cellular DNA content. 31 
Immunoblotting
The expression of c-MYC was assessed by immunoblots as previously described. 32 In brief, cells (10 6 ) were treated and harvested at various time intervals, and whole-cell pellets were lysed with detergent lysis buffer (1 ml/10 7 cells, 50 mM Tris-HCl buffer, pH 8.0, 150 mM NaCl, 1 mM DTT, 0.5 mM EDTA, 1% Nonidet P40, 0.5% sodium deoxycholate, 0.1% sodium dodecylsulfate, 100 g/ml phenylmethylsulfonyl fluoride, 1 g/ml aprotinin, 2 g/ml leupeptin and 100 M sodium vanadate) to obtain protein lysates. Protein concentrations were quantified using a bicinchoninic acid kit. Since c-MYC is a labile protein, cell lysates were not frozen, but stored at 4°C, until all protein lysates were prepared for a particular cell line, and then Western blots were performed immediately. Total protein (30 g) was separated by 10% SDS-PAGE, electroblotted to PVDF membranes, and blocked overnight with 5% non-fat dry milk. The membrane was incubated with a solution of the primary antibody (2.5 g/ml), prepared in 1% blocking solution, for 2 h at room temperature, washed three times for 15 min with PBS-T (PBS with 0.1%, v/v, Tween 20) , and incubated with a 1:2500 dilution of horseradish peroxidase-conjugated secondary antibody for 30 min at 37°C. Blots were again washed three times for 10 min each in PBS-T and developed by enhanced chemiluminescence (Amersham). Membranes were exposed to Kodak Biomax film and the resulting film was analyzed using Kodak (Rochester, NY, USA) 1D Image Analysis software. Membranes were then stripped and reprobed for the quantification of ␤-actin.
RT-PCR analysis
RNA was extracted from 10 6 cells using TRIzol Reagent (Invitrogen, Carlsbad, CA, USA). Following isopropanol preLeukemia cipitation, the pellet was washed in 75% aqueous ethanol and the RNA was dissolved in 25 l of diethyl pyrocarbonate (DEPC)-treated distilled water. Subsequently, the samples were stored at −80°C. RNA quantitation was performed by UV measurement at 260 nm. The cDNA synthesis was performed in a total volume of 10 l, containing 1 × TaqMan RT buffer, 5.5 M MgCl 2 , 2 mM dNTPs mixture, 2.5 M random hexamers, 4 U RNase inhibitor, 12.5 U MultiScribe RT (Perkin Elmer/Applied Biosystems) and 0.2 g of RNA. The reaction was performed for 10 min at 25°C, followed by 48°C for 30 min and a 5 min incubation step at 95°C. After the reaction, 10 l of DEPC-treated distilled water was added to each sample and 1 l was used for each PCR.
The PCR and subsequent analyses were performed in the GeneAmp 5700 Sequence Detection System (Applied Biosystems). Real-time quantitation was performed using the TaqMan technology of Applied Biosystems. c-Myc primers and probe sequences (5Ј to 3Ј) were as follows: CGTCTCCA-CACATCAGCACAA, TCTTGGCAGCAGGATAGTCCTT and TACGCAGCGCCTCCCTCCACTC (Applied Biosystems).
PCR reactions were performed in triplicate. The PCR reaction mixture contained 300 nM of both primers, 150 nM TaqMan probe, and 1 × TaqMan Universal Master Mix (Applied Biosystems). The reactions were first incubated at 50°C for 2 min, followed by 10 min at 95°C. The PCR itself consisted of 40 cycles with 15 s at 95°C and 1 min at 60°C each. The fluorescence signal was measured during the last 30 s of the annealing/extension phase. After the PCR, a fluorescence threshold value was set and threshold cycle (Ct) values were determined, ie, the fractional cycle at which the fluorescence signal reached this threshold. These values were used for further calculations.
␤-Actin (TaqMan PDAR control; Applied Biosystems) was used as an endogenous reference to correct for any differences in the amount of total RNA used for a reaction and to compensate for different levels of inhibition during reverse transcription of RNA into cDNA. c-Myc and ␤-actin expression were related to a standard curve derived from a serial dilution of K562 cDNA with dH 2 O. Also, c-myc and ␤-actin quantities were expressed in terms of ng of K562 RNA yielding the same level of expression. Subsequently, normalization was achieved by dividing the expression level of c-myc by the ␤-actin expression level. Finally, results were expressed as a percentage, where the level of c-myc observed in the DMSO-treated samples was considered as 100%.
Results
Cytotoxic and antiproliferative effects of brusatol on normal human lymphocytes and leukemic cells
A panel of 11 leukemic cell lines showing various chromosomal aberrations (Table 1) was selected and the effects of brusatol and bruceantin on cell viability and proliferation were tested. Evaluation of viability using the Trypan blue exclusion method demonstrated that brusatol was preferentially cytotoxic to the NB4, U937, BV173, SUPB13, RS4;11, Daudi and DHL-6 cell lines, showing IC 50 values of less than 25 ng/ml (Table 1) . On the other hand, HL-60, Kasumi-1 and Reh cell lines showed increased resistance to cytotoxic effects with IC 50 values in the range of 50-100 ng/ml. K562 and normal lymphocytic cells (stimulated with concanavalin A) were the least sensitive of all cells tested, demonstrating approximately 90% viability after 4 days of treatment with 100 ng/ml Peripheral human Ͼ100 Ͼ50 7.5 ± 0.3 3 ± 0.3 lymphocytes Cells were incubated with various concentrations of brusatol or bruceantin for 4 days and normal human lymphocytes were allowed to grow for 3 days in the presence of concanavalin A (0.4 g/ml) and various concentrations of brusatol. a Viability was determined by Trypan blue exclusion in duplicate samples. Control viabilities did not decrease from 90%. Results are expressed as median inhibitory cell concentrations of two independent experiments (± standard deviations). b Proliferation was assayed by 3 H thymidine incorporation with quadruplicate samples, as described in Materials and methods. Results are shown as median inhibitory cell concentrations of two independent experiments (± standard deviations).
of brusatol (Table 1) . Bruceantin (2, Figure 1 ), which differs from brusatol (1, Figure 1 ) by two methyl groups in the ester side chain at C-15, was more potent than brusatol in all cell lines tested (Table 1 ). There was no obvious correlation between cytotoxic activity and a particular chromosomal aberration.
We then examined the effects of brusatol on proliferation of normal human lymphocytes or leukemic cells by incorporation of 3 H thymidine into DNA over an 18 h incubation period, subsequent to exposure to various concentrations of brusatol for 4 days. Brusatol inhibited the proliferation of normal human lymphocytes, HL-60, K562, Kasumi-1, SUPB13, RS4;11 and Reh cells in a dose-dependent manner (Table 1) . Interestingly, these cell lines represent those that were most resistant to brusatol-mediated cytotoxicity, while the compound actually increased the amount of radioactive precursor incorporation in some cytotoxic-sensitive cell lines such as NB4, U937, BV173 and Daudi (data not shown).
In accordance with 3 H thymidine incorporation data, brusatol (25 ng/ml) significantly induced G 1 arrest (with concomitant decreases in S and/or G 2 /M phases) in asynchronious HL-60, K562, Kasumi-1, BV173, SUPB13 and Reh cells (Table 2) , and the G 1 block was complete at 72 h using a higher dose of 100 ng/ml (data not shown). NB4 and BV173 cells showed sub-G 1 peaks characteristic of apoptosis while U937 and RS4;11 cells did not (Table 2) , although loss of viability (as determined by Trypan blue exclusion) was similar for all four cell lines. Interestingly, U937 and RS4;11 cells showed a decrease in the G 1 phase and a significant increase in the S phase, characteristic of metabolic arrest.
Induction of differentiation by brusatol with various myeloid and lymphoblastic cell lines
Previous studies performed in our laboratory demonstrated that brusatol was able to induce differentiation of HL-60 cells in a concentration-dependent fashion. 29 In the current study, cells were treated with various concentrations of brusatol for 4 days and then harvested for evaluation of functional, enzymatic and cell membrane markers of differentiation.
Analysis of NBT reduction for evaluation of superoxide formation demonstrated myeloid maturation in five cell lines (HL-60, K562, NB4, U937 and BV173). The effect was dosedependent, as shown in Figure 2a . Peak inductions of 75% were observed in HL-60 and K562 cells. In addition, brusatol up-regulated the expression of NSE (a monocytic marker) in K562, Kasumi-1 and NB4 by approximately 50%, and in BV173 cells by approximately 35% (Figure 2b) .
We also analyzed membrane phenotype using flow cytometry with a set of four myeloid markers (CD11b, CD13, CD14 and CD15). Brusatol up-regulated CD11b in HL-60 and U937 cells, CD13 in HL-60, NB4 and U937 cells, and CD14 only in U937 cells, and down-regulated CD15 in HL-60, K562, NB4, U937 and RS4;11 cells (Table 3) . Thus, it was noted that brusatol induced a pattern of expression similar to that produced by macrophage inducers, with down-regulation of CD15 (granulocytic marker) and up-regulation of CD13 and CD11b (granulocytic/monocytic markers) in HL-60 and U937 cells (Table 3) .
It was of interest to note morphological changes characteristic of erythroid differentiation in two lymphoblastic cell lines (SUPB13 and RS4;11) as was shown for CML cell lines K562 and BV173 (ie, smaller cells devoid of nuclei with a pinkishbluish cytoplasm, Figure 3a) . Erythrophagocytosis by adjacent cells is also evident in some of the cell lines undergoing erythroid differentiation (Figure 3a) . This finding was supported by the production of hemoglobin in these cells, as shown by benzidine staining (Figure 3b) . Hemoglobin was upregulated dose dependently in SUPB13 and RS4;11 cells, as well as the CML cell lines K562 and BV173 (Figure 3b) .
Finally, we analyzed various membrane markers of B lymphocyte maturation (ie, CD20, superficial light chain kappa and HLA-DR) in SUPB13, RS4;11, Reh, Daudi and DHL-6. Table 2 Cell cycle effects of brusatol with various leukemic cell lines
Cell line
Control, 24 h Brusatol (25 ng/ml), 24 h HL-60 G 1 = 39.3 ± 1.3 G 1 = 68.7 ± 0.9* S = 50.8 ± 1.6 S = 13.0 ± 1.0** G 2 /M = 9.9 ± 2.8 G 2 /M = 18.3 ± 1.1
Cells were treated with solvent or brusatol (25 ng/ml) for 24 h, fixed in ethanol and stained with PI for flow cytometric analysis as described in Materials and methods. At least 10 000 cells were counted. Results are presented as the mean of triplicate samples (± standard deviation 
Irreversibility of brusatol effects on differentiation or cell death of leukemic cells
The irreversibility of brusatol effects on growth and differentiation of HL-60 cells was tested using withdrawal assays during a 4 day experiment. Withdrawal of brusatol after 48 h of exposure resulted in the induction of 41% of cells to differentiate (compared to 46% without withdrawal), while maintaining cellular viability higher than 80% and the same cell density (0.21 × 10 of cells induced to mature is similar for time exposures of 48, 72 or 96 h, indicating that there is no further need for the presence of the compound after 48 h, where cells have become committed to differentiate. However, the viability percentages were greatly reduced with increasing time of exposure to the drug (82% at 48 h; 56% at 72 h; 45% at 96 h), indicating the cytotoxic effect is cumulative (Figure 4) . Therefore, when comparing the concentration required to induce 50% of cells to differentiate with the concentration needed to kill 50% of cells using 4-day or 2-day exposure protocols, a 10-fold increase in selectivity was observed when the 2-day protocol was used (differentiation induction ED 50 = 17.5 ng/ml for both protocols; cytotoxic IC 50 = 25 ng/ml for a 4-day protocol and 250 ng/ml for a 2-day protocol). Similar effects of withdrawing brusatol were observed in other cell lines, such as K562 and SUPB13, where commitment toward differentiation was obtained with 48 h of exposure to brusatol (data not shown). Withdrawal studies also demonstrated that 48 h of brusatol (25 ng/ml) treatment is sufficient to induce Cells were induced to differentiate with the indicated concentrations of brusatol using a 4-day protocol and then analyzed for membrane markers of differentiation as described in Materials and methods. Results are expressed as the specific mean fluorescence intensity (ratio of antigen antibody fluorescence over isotype antibody fluorescence), and represents the mean of two independent studies. Kasumi-1 and BV173 did not show any changes between the control and treated cells. *Significantly different from control values, determined by Student's t-test (P Ͼ 0.05).
100% cytotoxicity in NB4, Daudi and DHL-6 cells, but not in the remaining cell lines (data not shown).
Brusatol down-regulates c-myc
Since c-myc deregulation is involved in blockage of differentiation and proliferation, we analyzed the status of c-myc in 10 cell lines after a short exposure (4 or 24 h) to brusatol (25 ng/ml) or bruceantin (10 ng/ml). The level of c-MYC protein was high in control samples of HL-60, K562, Kasumi-1, SUPB13, Reh and Daudi cells ( Figure 5 ). Moderate levels of c-MYC protein were observed in NB4, U937, BV173 and RS4;11 cells. Brusatol and bruceantin induced down-regulation of c-MYC protein levels in all cell lines, but greatest reduction occurred in HL-60, K562, NB4, U937, BV173, RS4;11 and Daudi cells ( Figures 5 and 6 , Table 4 ). In contrast, c-MYC protein levels in Kasumi-1, SUPB13 and Reh cells were reduced to a lesser extent when treated with brusatol ( Figures 5 and 6 , Table 4 ). Cytotoxic-sensitive cell lines NB4, U937, BV173, RS4;11 and Daudi cells showed marked decreases of c-MYC at 24 h, while those cell lines that manifested terminal differentiation (HL-60, K562 and SUPB13) showed the lowest levels of c-MYC protein at 4 h. Interestingly, brusatol also down-regulated c-MYC expression in normal human lymphocytes, although control levels were low (data not shown).
Analysis of c-myc mRNA using real time RT-PCR revealed that brusatol and bruceantin produced minor effects on the transcriptional regulation of c-myc in those cell lines where protein expression was markedly reduced (Figure 6 , Tables 4  and 5 ). For example, a 4 h treatment with brusatol induced a decrease in c-myc mRNA levels by ෂ40 and ෂ50% in K562 and HL-60 cells, respectively. However, c-MYC protein levels were decreased by 94 and 100%, respectively. It is important to note that both protein and mRNA evaluations were performed in a parallel fashion, therefore avoiding experimental errors due to compound stability and cell line senescence. These data suggest that brusatol and bruceantin are affecting translational regulation of c-myc expression. Interestingly, the opposite effect was observed in Kasumi-1 and SUPB13 cells, where c-myc transcript levels were significantly reduced, but c-MYC protein expression was similar to control (solventtreated) samples ( Figure 6 , Tables 4 and 5) .
Discussion
We currently demonstrate the potential of brusatol and bruceantin to induce differentiation, antiproliferative and differential cytotoxic effects in a panel of 11 leukemic cell lines. Cell growth and differentiation studies with this panel revealed two patterns of activity. One group of cell lines, namely HL-60, K562, Kasumi-1 and Reh, were less responsive to brusatol-or bruceantin-mediated cytotoxicity, but their growth was arrested at the G 1 phase. Furthermore, these cells (with the exception of Reh) demonstrated some degree of differentiation, based on one or more markers of this process. The second group, comprised of NB4, U937, BV173, SUPB13, RS4;11, Daudi and DHL-6 cells, were extremely sensitive to brusatol or bruceantin, as shown by marked cytotoxic effects, but with little induction of differentiation. Cell cycle analyses demonstrated apoptotic peaks with NB4 and BV173, an arrest in G 1 phase with SUPB13, and an arrest in S phase with U937 and RS4;11, suggesting different cytotoxic mechanisms may be triggered. Although the reason for the difference in the response of the various cell lines is unknown, it was observed that brusatol exerted strong cytotoxicity in those cell lines reported to express wild-type p53, including NB4, U937, BV173 and Daudi, [43] [44] [45] while some of the less sensitive cell lines have been reported to be p53-null or mutant p53-expressing cell lines, eg, HL-60, K562, Kasumi-1 and Reh. [43] [44] [45] [46] [47] The mechanism of action of various differentiation and apoptosis inducers remains largely unknown, but the participation of certain key genes have been demonstrated for some active compounds, such as ATRA and CGP 57148. 6, 7 Evaluation of c-myc mRNA and protein expression in our panel of leukemic cell lines revealed brusatol-and bruceantin-induced marked decreases. However, with the exceptions of Kasumi-1, SUPB13 and Reh cells, down-regulation of c-myc mRNA was less intense than the decrease observed with c-MYC pro- tein levels. These data suggest translational (eg, regulation of the internal ribosome entry segment of c-myc mRNA) and/or post-translational (eg, ubiquitination by proteasome complexes) regulation of this oncogene. Brusatol-and bruceantin-mediated early down-regulation of c-MYC correlated with induced differentiation in various cell lines, including monocytic differentiation in HL-60, K562, NB4 and U937,
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Figure 4
Commitment toward differentiation of HL-60 cells is obtained at 48 h of exposure to brusatol. The assay lasted for 4 days (96 h) and then cells were analyzed for viability and differentiation markers. HL-60 cells were treated with 25 ng/ml of brusatol which was withdrawn after the indicated time intervals, and cells were resuspended in fresh complete media for the remaining time. Results are shown as the mean of duplicate samples (± standard deviation).
and moderate erythrocytic differentiation in BV173, K562, SUPB13, and RS4;11.
The biological consequences of down-regulating c-myc are numerous. In the hematopoietic system, this gene inhibits differentiation [11] [12] [13] and functions as a leukemogenic protein in various lymphomas and leukemias. 8, 48 Moreover, it is known that deregulation of c-myc, in conjunction with p53 and bcl-2 mutations, is associated with a malignant phenotype. 49 For instance, chronic myelogenous leukemia cell lines possessing negligible levels of wild-type p53 (like K562) also expressed high levels of c-myc, 43 while the reverse phenomenon was observed in CML cell lines that express high levels of wildtype p53 (such as BV173). These and other studies have led to the hypothesis that myc deregulation decreases the probability of maturation, while p53 and bcl-2 mutations enhance cell survival, therefore favoring leukemic cell renewal. 49 Some studies, using c-myc knockout cells or mice, support the idea that c-myc down-regulation results in withdrawal from the cell cycle with a G 1 arrest. Therefore, c-MYC functions as a switch that promotes entry into and prevents exit from the cell division cycle; it is not essential for cellular growth, but controls the commitment of cells to divide or not to divide. [50] [51] [52] In this study, cell growth arrest at the G 1 or S phases correlated with decreases of c-MYC in HL-60, K562, U937, BV173, RS4;11 and Reh cells. Thus, we speculate that brusatol triggered cell death mechanisms preferentially in those cell lines with wild-type p53 protein expression, while terminal differ-
Figure 5
Brusatol down-regulates c-myc expression. Cells were treated with solvent (0.1% v/v DMSO, control), brusatol (25 ng/ml) or bruceantin (10 ng/ml) for 4 or 24 h, and then analyzed by Western blotting. Membranes were probed for c-MYC, and then stripped and probed for ␤-actin as an internal control. Densitometric analyses are summarized in Table 4. entiation was triggered in cell lines without wild-type p53 or with mutant p53.
In summary, we have shown that quassinoids mediate strong cytotoxic effects in various cell lines while sparing normal human lymphocytes, and inhibit proliferation primarily by producing a G 0 /G 1 arrest. This arrest is associated with subsequent expression of various markers of differentiation, and differentiation effects are irreversible following 48 h drug exposures. In addition, cell lines that were most sensitive to brusatol-mediated cytotoxicity were eliminated with only 48 h of exposure. Notably, cytotoxic or differentiating effects were observed in the concentration range of 10 to 100 ng/ml, and 25 ng/ml seemed to be a sufficient in vitro concentration (10 ng/ml for bruceantin) to mediate these growth inhibitory responses. This is of importance since pharmacokinetic studies with human beings have demonstrated that a single intravenous injection of 3 mg/m 2 bruceantin can yield a blood level of 22 ng/ml. 20 Moreover, this dose was well tolerated with few side-effects, including a lack of hematologic toxicity, 24 and normal lymphocytes were considerably less sensitive to the cytotoxic effects of brusatol or bruceantin. These observations suggest that a non-toxic concentration of brusatol administered for a short exposure time is sufficient to induce Cells were treated with brusatol (25 ng/ml) or bruceantin (10 ng/ml) for 4 or 24 h, and then analyzed for c-myc mRNA and protein expression (Tables 4 and 5 ). Results are shown as a percentage of c-myc mRNA or protein expression, relative to levels observed in cells treated with solvent (0.1%, v/v, DMSO) only.
Table 4
Effect of brusatol and bruceantin on c-MYC oncoprotein expression in various leukemic cell lines
Cell line 4 h 24 h
Brusatol Bruceantin Brusatol Bruceantin (25 ng/ml) (10 ng/ml) (25 ng/ml) (10 ng/ml) HL-60  0  3  17  57  K562  6  2  13  12  Kasumi-1  66  70  112  87  NB4  0  0  0  0  U937  5  40  12  44  BV173  22  28  41  12  SUPB13  52  42  41  63  RS4;11  20  30  10  6  Reh  66  44  32  40  Daudi  79  67  10  2 Cells were treated with brusatol (25 ng/ml) or bruceantin (10 ng/ml) for 4 or 24 h, and then analyzed for c-MYC and ␤-actin expression using Western blotting techniques. Results are expressed as percentage of c-MYC oncoprotein of control (0.1%, v/v, DMSO-treated cells) values at the corresponding time point. Results were normalized relative to ␤-actin. Bands are shown in Figure 5 , and histograms are shown in Figure 6 .
